Research Paper:
Ameliorative Effect of Trevo Dietary Supplement Against Lead Acetate Nephrotoxicity

Omotayo B. Ilesanmi1*, Eni-yinimi Solomon Agoro1

1. Department of Biochemistry, Faculty of Science, Federal University Otuoke, Bayelsa State, Nigeria.

Background: Trevo is a nutritional supplement with numerous bioactive natural products, with detoxifying and antioxidant properties. The purpose of this study was to investigate the ability of Trevo to protect against oxidative stress induced by lead in the kidneys of male Wistar rats.

Methods: Thirty-five healthy male Wistar rats were divided into five groups of seven rats each, using a randomized design. I=control; II=15 mg/kg of lead acetate (PbA); III=2 ml/kg of trevo+PbA; IV=5 ml/kg of trevo+PbA; V=5 ml/kg of trevo. Animals were treated with trevo for five days before co-administration with lead intraperitoneally for 10 consecutive days. Animals were sacrificed 24hr after the last administration, blood samples were collected via cardiac puncture, and processed for assessment of urea, creatinine, and uric acid (UA), while the kidney samples were excised and processed for the following biochemical assays: Malondialdehyde (MDA), Glutathione-S-Transferase (GST), Catalase (CAT), Superoxide Dismutase (SOD), and Reduced Glutathione (GSH).

Results: Injection of PbA caused a significant increase in the serum levels of urea, creatinine, and uric acid, and a significant increase (P<0.001) in the MDA concentration, and decreases in GSH concentration, CAT, SOD, and GST activities (P<0.05) as compared to the controls. Pretreatment with trevo prevented the oxidative stress induced by lead acetate in the kidney tissue samples and improve the renal function. The protective effect was evident at 5 ml/kg of trevo.

Conclusion: The results showed that trevo was nephroprotective against lead toxicity and the activity might be linked to the presence of numerous antioxidant phytochemicals present in trevo.

Keywords: Lead, Nephrotoxicity, Oxidative stress, Reactive oxygen species, Natural product

Introduction

The ubiquitous nature of lead has made it one of the most studied heavy metals. Lead is an environmental pollutant that is nonbiodegradable with a very long half-life, thus, it can stay in the environment for a long time undetected unless it is present in high concentrations. Human activities have further increased the concentration of lead in the atmosphere [1-3]. Industrial growth in automobiles, electrical, agricultural, and construction industries contribute to the observed increased concentration of lead in the environment [1]. The toxic effects of lead have been reported in the organs of experimental animals [4-6]. Lead has been reported to damage the nervous, reproductive, hematopoietic, respiratory and excretory systems, such as kidneys and liver [7-10]. Kidneys are particularly prone to the toxic effect of lead, since they play an important role in its excretion [4, 11, 12]. Biologically, lead has
no health benefit to humans; however, its bioaccumulation in the body leads to various injuries as stated earlier [13]. The presence of non-enzymatic proteins with high affinities for lead in the kidneys also increases their susceptibility to its toxicity [14, 15]. Morphologically, lead has been reported to cause interstitial lesions, glomerular sclerosis, fibrosis, and nephropathy.

One of the agreed upon mechanisms of lead-induced nephrotoxicity is oxidative stress [16]. The idea is to look for safe and effective antioxidant natural compounds to counter lead poisoning. Lead is known to alter the redox mechanism in the kidneys, thereby increasing Reactive Oxygen Species (ROS) and diminishing the antioxidant systems [17]. The common treatment for lead poisoning is through the use of metal chelators. Some of the approved treatments include dimercaprol dimercaptosuccinic acid, ethylene diamine tetra-acetic acid, penicillamine, and succimer. Some of these chelators have been reported to adversely affect the digestive tract and bones, and cause muscle weakness while some of them spread lead to other bodily organs [18-20]. The availability of rich antioxidants and phytochemicals with proven metal chelating properties makes them good candidates for treating lead poisoning. The fact that most of these phytochemicals are present in our staple foods, vegetables, and fruits, suggests that they are safe compared to synthetic drugs and chemicals with known toxicities.

Trévo is a phytochemical-rich supplement produced in the USA. It is commercially promoted as a blood purifying, immune booster, detoxifier, and regenerating product that improves the health and well-being of individuals. Also, the anticancer, and the protective effects of trevo on the liver, heart and nervous system against various toxins have been reported [21-23]. In an earlier study, we have reported the protective activity of trévo against cyanide-induced nephrotoxicity [24]. The current study was planned to investigate the protective effect of trévo against lead-induced nephrotoxicity in male Wištar rats.

Materials and Methods

**Chemicals and reagents:** Lead acetate (PbA), Reduced glutathione, Thiobarbituric Acid (TBA), Trichloroacetic Acid (TCA), Chloro Dinitrobenzene (CDNB), and Nicotinamide Adenine Dinucleotide (NADH) were purchased from Sigma-Aldrich (Darmstadt, Germany). The kits for creatinine, urea and uric acid were obtained from Randox laboratories Ltd (Crumlin, UK). Trévo was a product of Trévo TM LLC (Oklahoma City, USA). All chemicals used in this study were of analytical grades.

**Experimental design:** Thirty-five male Wištar rats, weighing 170±10g, were purchased from the Central Animal House, University of Benin, Edo State, Nigeria, and were used in this study. The animals were housed in well-ventilated cages and were provided water and food *ad libitum*. All experimental protocols complied with the guidelines of the Helsinki Declaration of 1975.

Animals were orally administrated 2 ml/kg of trévo for two days prior to co-administration with 15 mg/kg PbA for 12 consecutive days. The animal groups were as follows:

**Group 1:** administered the vehicle (distilled water).

**Group 2:** administered 15 mg/kg of PbA Intraperitoneally (IP).

**Group 3:** orally administered 2 ml/kg of trevo before the IP administration of PbA.

**Group 4:** orally administered 5 ml/kg of trevo before the IP administration of PbA.

**Group 5:** orally administered 5 ml/kg of trevo only.

**Processing the kidneys:** 24-hr after the last administration, animals were sacrificed by cervical dislocation and the kidneys were removed, rinsed, and homogenized in phosphate buffer saline (0.1M, pH 7.4), resulting in a 10% w/v homogenate. The homogenate was centrifuged at 15000 rpm for 10 min at 4oC to obtain a clear supernatant that was used for the biochemical assays.

**Preparation of sera:** Blood samples were collected from the rats’ heart by cardiac puncture into sample tubes. The blood samples were centrifuged at 3,000g for 10 min in a MSC bench centrifuge to obtain the sera, which were used for the estimation of the rats’ renal function.

**Renal function biomarkers:** The concentrations of urea, creatinine, and uric acid were determined in the sera following the instruction from the kits’ manuals.

**Biochemical assays**

**Estimation of oxidants in the kidneys:** The level of oxidative stress was determined by measuring the amount of Malonaldehyde (MDA) formed from Lipid peroxidation (LPO) in the kidney tissue samples according to a previously described method [25].

**Estimation of antioxidants in the kidneys:** The concentration of Glutathione (GSH) was measured ac-
According to an established method [26]. Catalase (CAT) activity was determined as described earlier [27]. The activity of Superoxide Dismutase (SOD) was measured as described by an earlier study [28].

**Glutathione transferase assay:** The activity of GST in the kidneys was assessed as described previously [29].

**Statistical analyses:** The data were analyzed statistically using GraphPad Prism 6.01 software. One way Analysis of Variance (ANOVA) was used to compare the values between groups while Duncan’s multiple range test was used as descriptive. All values were expressed as the Mean±SD of five animals per group. The statistical significance was considered at a minimum of P<0.05 level.

**Results**

**Serum markers of renal damage:** Table 1 summarizes the effect of trevo and PbA on the serum levels of urea, creatinine, and uric acid. The exposure of the rats to PbA caused a significant increase in the serum levels of urea, uric acid, and creatinine as compared to those of the controls (P<0.001). Pretreatment of the rats with either 2ml/kg or 5 ml/kg of trevo significantly prevented the renal damage induced by PbA as observed by significant decreases in the serum levels of urea, creatinine, and uric acid, compared to those in the untreated animals (P<0.01-0.001). The administration of 5 ml/kg of trevo to the rats had no significant effect on serum levels of urea, uric acid, and creatinine, compared to those of the control animals (P>0.05).

**Effect of lead acetate and trevo on the oxidative stress:** Figure 1 shows the effect of trevo on the renal Malondialdehyde (MDA) level in the rats following exposure to PbA. The lead acetate caused a significant increase in the kidneys’ MDA level as compared to that of the control animals (P<0.001). The administration of 2ml/kg or 5 ml/kg of trevo prevented the inhibitory activities of CAT and SOD caused by PbA exposure. These were evident by the significant increases in the activities of CAT and SOD, as compared to those observed in the untreated group (P>0.05). The administration of 5 ml/kg of trevo had no significant effect on the rats, as compared to that observed in the control animals (P>0.05).

![Figure 1](image1.png)

**Effects on Glutathione-S-Transferase (GST) activity in the rats’ kidneys:** Figure 5 shows the effects of PBA and trevo on the activity of Catalase (CAT) and Superoxide Dismutase (SOD). Lead acetate significantly inhibited the activities of CAT and SOD in the kidney tissue samples of the rats as compared to that of the control animals (P<0.001). The administration of 2ml/kg or 5 ml/kg of trevo prevented the inhibitory activities of CAT and SOD caused by PbA exposure. These were evident by the significant increases in the activities of CAT and SOD, as compared to those observed in the untreated group (P>0.05). The administration of 5 ml/kg of trevo had no significant effect on the GST activity as compared to those of the control rats (P>0.05).

**Table 1. Serum urea, uric acid and creatinine levels in control and in all experimental groups (n=7)**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Urea (mg/dl)</th>
<th>Uric Acid (mg/dl)</th>
<th>Creatinine (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>5.3±0.59</td>
<td>19.8±1.70</td>
<td>5.4±0.73</td>
</tr>
<tr>
<td>15 mg/kg PbA</td>
<td>9.8±0.43***</td>
<td>54.5±5.50***</td>
<td>27.1±2.17***</td>
</tr>
<tr>
<td>2 ml/kg trevo+PbA</td>
<td>8.1±0.85**</td>
<td>50.0±1.83</td>
<td>23.9±1.65**</td>
</tr>
<tr>
<td>5 ml/kg trevo+PbA</td>
<td>6.9±0.71***</td>
<td>42.0±2.79***</td>
<td>13.2±1.37***</td>
</tr>
<tr>
<td>5 ml/kg trevo</td>
<td>5.6±0.22</td>
<td>14.2±1.67</td>
<td>6.8±0.87</td>
</tr>
</tbody>
</table>

***P<0.001= Control group vs PbA; **P<0.01= PbA vs 2 ml/kg trevo; ***P<0.001= PbA vs treatment groups (2 & 5 ml/kg, trevo); PbA= Lead acetate.
caused an insignificant increase in the GST activity compared to that of the controls (P<0.05).

**Discussion**

This study investigated the nephroprotective effect of trévo following lead acetate exposure in rats. Generally, the increased urea and creatinine levels in the blood are often linked to kidney impairment. The high concentrations of urea and creatinine in the blood after lead exposure confirm its nephrotoxic effect. The rise of urea and creatinine is primarily due to increased protein turnover and failure of the glomeruli to reabsorb and prevent their leakage into the blood [30]. Another important marker

Figure 1. The concentration of lipid peroxides product - Malondialdehyde (MDA), in the kidney tissue of male rats. After a 2-day oral administration of trévo and 12-day co-administration of PbA (15 mg/kg) intraperitoneally. Data are shown as Means±SD for 7 animals. Statistically significant differences were: "P<0.001=control vs PbA; "**P<0.001" PbA vs treatment groups (2- and 5 ml/kg of trévo). PbA: Lead acetate.

Figure 2. The concentration of non-enzymatic antioxidant-reduced Glutathione (GSH) in the kidney tissue of male rats. After a 2-day oral administration of trévo and 12-day co-administration of PbA (15 mg/kg) intraperitoneally. Data are shown as Means±SD for 7 animals. Statistically significant differences: ""P<0.001=control vs PbA; "***P<0.001" PbA vs 5 ml/kg of trévo. PbA: Lead acetate.

Figure 3. The catalase activity in the kidney tissue of male rats after 2 day- oral administration of trévo and 12-day co-administration with PbA (15 mg/kg) intraperitoneally. Data are shown as Means±SD for 7 animals. Statistically significant differences: ""P<0.001=control vs PbA; "P<0.05" PbA vs 2ml/kg of trévo; "***P<0.001" PbA vs 5 ml/kg of trévo. PbA:Lead acetate.

Figure 4. The Superoxide Dismutase (SOD) activity in the kidney tissue of male rats after 2 day- oral administration of trévo and 12-day co-administration with PbA (15 mg/kg) intraperitoneally. Data are shown as Means±SD for 7 animals. Statistically significant differences: ""P<0.001=control vs PbA; "***P<0.001" PbA vs 5 ml/kg of trévo. PbA:Lead acetate.
of renal injury is the rise in uric acid in the serum, which is produced by purine metabolism. Our experimental results demonstrated that exposure to lead acetate elevated the serum uric acid level, consistent with those reported by earlier investigators [31-34].

The mechanism by which lead induces oxidative stress involves increased damages to macromolecules, such as lipids and depletion of the antioxidant system in the body [35-38]. Malondialdehyde is the most sensitive biomarker of oxidative stress, which is formed by the reaction of ROS with fatty acids [39]. The results of our experiments demonstrated that the MDA level was highly elevated in the rat kidneys after lead exposure, corroborating its role in ROS generation.

Glutathione is one of the major non-enzymatic antioxidants in the maintenance of redox status in the living organisms. Its depletion has been implicated in many diseases linked to oxidative stress. It is involved in drug metabolism, antioxidant defense, and regulation of certain cellular metabolic functions. The present study provided evidence of oxidative stress following exposure to lead as evident by the presence of low GSH concentrations in the rat kidneys. In this context, our results are similar to those reported by two earlier studies [13, 17]. They observed a significant decrease in the GSH concentration of the rats’ kidneys after their exposure to lead.

Figure 5. The Glutathione-S-Transferase (GST) activity in the kidney tissue of male rats

<table>
<thead>
<tr>
<th>Condition</th>
<th>GST Activity (nmole CDNB conjugated/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>80</td>
</tr>
<tr>
<td>PbA (15 mg/kg)</td>
<td>60</td>
</tr>
<tr>
<td>Trévo (2 ml/kg)+PbA</td>
<td>40</td>
</tr>
<tr>
<td>Trévo (6 ml/kg)+PbA</td>
<td>20</td>
</tr>
<tr>
<td>Trévo (5 ml/kg)</td>
<td>0</td>
</tr>
</tbody>
</table>

Catalase (CAT) is an antioxidant enzyme widely distributed in the body. It catalyzes the conversion of hydrogen peroxide to water and oxygen. The activity of CAT is generally reduced in most organs after exposure to toxic chemicals [11, 40]. Our results showed that lead acetate caused a significant decrease in the CAT activity in the kidneys. This enzyme is known to be protective against reactive hydroxyl radicals in animal models, and is reduced as a part of the mechanism involved in the deleterious effects of lead [1, 41].

Another antioxidant enzyme of significance is Superoxide Dismutase (SOD), which catalyzes the conversion of superoxide to hydrogen peroxide. Superoxide anion is one of the deadliest radicals that if not quickly eliminated, can lead to the oxidation and inactivation of various biological molecules. The reduction in SOD activity indicates a major oxidative stress. The results of the current study showed that the administration of lead acetate caused a significant decrease in the SOD activity, confirming its oxidative effect, which was consistent with the observations of earlier studies [42, 43]. Both SOD and CAT serve to clear the body of ROS, thus their reduction can be the mechanisms by which they lead to nephrotoxic alterations.

Glutathione Transferase (GST) is a conjugating enzyme involved in drug metabolism and detoxification. Its activity can be reduced due to low concentration of GSH, toxic chemicals, or the suppressed expression of the genes involved in their synthesis. In our study, the GST activity was significantly reduced in the rats’ kidney samples after exposure to lead acetate. The low GST activity can be linked to its destruction due to lead toxicity, in addition to other potential factors. Our experimental results indicated that there was a significant decrease in the kidneys’ GST concentration induced by the lead toxicity. This molecule is critical in the antioxidant defense. It helps in the detoxification of xenobiotics and protection against oxidative stress [44, 45].

Treatment with trevo five days prior to exposure to the lead acetate reduced the serum concentrations of urea, creatinine, and uric acid, and caused a noticeable improvement in the kidneys function. In addition, the trevo treatment also reduced the kidney concentration of MDA, and increased the GSH, CAT, SOD, and GST concentrations. The nephroprotective activity of trevo against lead toxicity can be linked to the presence of various antioxidant phytochemicals in that product. Plants rich antioxidant have been effective in countering lead toxicity, since they serve as metal chelators, radical scavengers and terminator of various oxidative processes [1, 4, 13, 17, 39, 42, 46].
Conclusion

The pretreatment with trévo was able to prevent the leakage of molecules confined to the rats’ kidneys into their sera due to exposure to lead acetate. Further, trévo at 5 ml/kg was able to limit the alteration in redox homeostasis against the adverse effects of lead acetate on the kidneys of the rats. Though it had minimal effect on GST, overall, trévo at the 5 ml/kg dosage was effective as a nephroprotective product in combating the oxidative damage induced by lead toxicity. The antioxidant activity is likely to be linked to the presence of bioactive compounds in trevo.

Limitations of the study: One of our challenges was the lack of resources to conduct morphological changes in the kidney tissues, quantification of lead in the blood and the tissue samples of the treated rats, and the molecular mechanisms of the protective effects of the trévo.

Recommendations for future studies: Further studies are recommended to investigate the protective effect of trévo on other organ tissues damaged by lead acetate.

Ethical Considerations

Compliance with ethical guidelines

All of the rats used in this study were healthy and treated according to the guidelines of the Helsinki Declaration of 1975 for the care and use of laboratory animals. The experimental design was approved by the ethics committee on Animal Research and Treatment (ART) of the Federal University Otuoke, Nigeria (Code: ART2021005). In specific terms, the experiments were conducted in the animal house of the Department of Biochemistry, Faculty of Science, Federal University Otuoke between February and June 2021.

Funding

The project was self-funded only, as part of ongoing research on pharmacological activity of Trevor.

Authors’ contributions

Both authors contributed equally in the development of the manuscript.

Conflict of interest

The authors declared no conflict of interest.

References


